CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel cancer therapy that targets the Myc protein, a key player in tumor growth. By utilizing a unique Myc mutant, Omomyc, the approach aims to inhibit cancer cell proliferation with minimal side effects and no resistance, paving the way for a new treatment for various cancers.
Current cancer therapies target redundant cellular functions often compensated for by cancer cells, resulting in resistance to treatment.
Here we propose an innovative approach to inhibit Myc, a non-redundant and “most-wanted” therapeutic target for human cancer.
Targeting Myc has long been considered unfeasible because of the potentially catastrophic side effects in normal tissues.
Against this dogma, we showed that Myc inhibition by Omomyc, a Myc mutant designed by Dr.
Soucek, has a dramatic t…
FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
